Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Harvard Business School
Colorcon
Dow
Medtronic

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Antares Pharma Inc Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for ANTARES PHARMA INC, and when can generic versions of ANTARES PHARMA INC drugs launch?

ANTARES PHARMA INC has three approved drugs.

There are sixteen US patents protecting ANTARES PHARMA INC drugs.

There are sixty patent family members on ANTARES PHARMA INC drugs in fifteen countries.

Summary for Antares Pharma Inc
International Patents:60
US Patents:16
Tradenames:4
Ingredients:3
NDAs:3
Patent Litigation for Antares Pharma Inc: See patent lawsuits for Antares Pharma Inc

Drugs and US Patents for Antares Pharma Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-002 Sep 28, 2018 RX Yes Yes 9,533,102   Start Trial Y   Start Trial
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-001 Sep 28, 2018 RX Yes Yes 9,629,959   Start Trial Y   Start Trial
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-003 Sep 28, 2018 RX Yes Yes 9,180,259   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes 8,945,063   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-008 Mar 24, 2016 RX Yes Yes 8,480,631   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 RX Yes Yes RE44846   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No 8,579,865   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Antares Pharma Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 7,744,582   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 7,744,582   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-004 Oct 11, 2013 RE44847   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RE44846   Start Trial
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-003 Sep 28, 2018 RE44847   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 RE44846   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RE44847   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
Express Scripts
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.